Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients
Lists
Only you see this
Abstract
To the editor:
Delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis is a potentially life-threatening complication of sickle cell disease (SCD) occurring 5 to 20 days after transfusion.[1][1] Patients display symptoms of severe vaso-occlusive crisis (VOC), associated with the
BibTeX
@inproceedings{dumas2016eculizumab,
author = {Guillaume Dumas and Anoosha Habibi and Thierry Onimus and Jean‐Claude Merle and Keyvan Razazi and Armand Mekontso Dessap and Frédéric Galactéros and Marc Michel and Véronique Frémeaux‐Bacchi and France Pirenne and Pablo Bartolucci},
title = {{Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients}},
booktitle = {Blood},
year = {2016},
doi = {10.1182/blood-2015-09-669770},
}Loading related content...